Programmed Cell Death News and Research

RSS

Myrexis to present Phase 2 monotherapy study results of Azixa in patients with GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day, to be held November 18-21, 2010 in Montreal, Canada.

22 Oct 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

21 Oct 2010

Research on Reaper protein provides new treatment strategies for cancer

Our cells live ever on the verge of suicide, requiring the close attention of a team of molecules to prevent the cells from pulling the trigger. This self-destructive tendency can be a very good thing, as when dangerous precancerous cells are permitted to kill themselves, but it can also go horribly wrong, destroying brain cells that store memories, for instance. Rockefeller University scientists are parsing this perilous arrangement in ever finer detail in hopes that understanding the basic mechanisms of programmed cell death, or apoptosis, will enable them eventually to manipulate the process to kill the cells we want to kill and protect the ones we don't.

21 Oct 2010

New approaches to explore causes of autoimmunity and immune deficiency diseases

A newly identified regulatory process affecting the biology of immune system T cells should give scientists new approaches to explore the causes of autoimmunity and immune deficiency diseases.

20 Oct 2010

Tips to improve cellular prostate health

Prostate cancer is one of the most common cancers in America and may lead to more than 32,000 deaths this year. Medical Doctor and cancer expert, Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer.

19 Oct 2010

BD, Walter and Eliza Hall Institute collaborate to commercialize antibodies

The Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, has entered a collaboration with New Jersey based medical technology company BD to evaluate and potentially develop for research and diagnostic use some of the institute's reagents.

19 Oct 2010

ARTS protein increases apoptosis mechanism to balance stem cells' regenerative power: Research

Stem cells, the prodigious precursors of all the tissues in our body, can make almost anything, given the right circumstances. Including, unfortunately, cancer. Now research from Rockefeller University shows that having too many stem cells, or stem cells that live for too long, can increase the odds of developing cancer.

15 Oct 2010

Researchers find STIM1 protein inhibits voltage-operated calcium channels

A calcium sensing protein, STIM1, known to activate store-operated calcium channels has been found to also inhibit voltage-operated calcium channels, according to researchers at Temple University.

4 Oct 2010

Recommendations for prostate cancer prevention and treatment

In light of Prostate Cancer Awareness month, integrative medicine pioneer and cancer expert Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer. As a well known specialist in the field of integrative prostate cancer therapy, Dr. Eliaz strategically combines ancient and modern healing modalities into a holistic practice of medicine by successfully incorporating the most effective and well researched therapies available in conventional and complementary medicine.

21 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

Research suggests blocking HMGB1 protein can benefit cancer patients

Like some people, cells eat when they are under pressure-but they consume parts of themselves. A multi-function protein helps control this form of cannibalism, according to a study in the September 6 issue of the Journal of Cell Biology.

7 Sep 2010

New peer-reviewed study on chemopreventive effects of Protandim

LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.

3 Sep 2010

Research on fruit fly provides inroads into understanding cancer development

Changes to proteins in a cell underlay many cancers. Rui Martinho at the Instituto Gulbenkian de Ci-ncia (IGC), in Portugal, in collaboration with researchers in Ghent (Belgium) and Bergen (Norway) will use the fruit fly to understand exactly how changes to proteins, identified in the test-tube, impact on the way cells divide in a living organism

24 Aug 2010

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time.

18 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Study links sea sponge genome sequence with first animals and cancer

The sponge, which was not recognized as an animal until the 19th century, is now the simplest and most ancient group of animals to have their genome sequenced. In a paper appearing in the August 5 issue of the journal Nature, a team of researchers led by Daniel Rokhsar of the University of California, Berkeley, and the Department of Energy's Joint Genome Institute (JGI), report the draft genome sequence of the sea sponge Amphimedon queenslandica and several insights the genome gives into the origins of both the first animals and cancer.

5 Aug 2010

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies.

3 Aug 2010

Body’s natural cell suicide program may trigger tumor development: Study

Cancer research springs a surprise. Researchers at Walter and Eliza Hall Institute in Melbourne have found that programmed cell death (apoptosis) or cell suicide plays a role in tumor development. This process is an important phenomenon in our body as it helps remove damaged cells. Now apoptosis has been found to be protective against cancer formation and autoimmune diseases.

1 Aug 2010

New study reveals potential role of TGF-β1 in kidney disease

Fibrosis in the kidney is one of the key causes of progressive renal failure. High levels of the inflammatory molecule TGF-β1 in the kidney tubules due to tissue damage can cause fibrosis as well as nephron degeneration, resulting in loss of kidney function. To clarify the mechanisms regulating TGF-β1-mediated renal fibrosis, Koesters et al expressed high levels of TGF-β1 in renal tubules of mice. Nephron degeneration in this system was mediated by decomposition of the tubular cells. These data suggest that TGF-β1 may play a novel role in cell death of renal cells, thus contributing to renal fibrosis.

28 Jul 2010

Calcium transfer impacts fuel mechanism for normal cell metabolism

University of Pennsylvania School of Medicine researchers have described a previously unknown biological mechanism in cells that prevents them from cannibalizing themselves for fuel. The mechanism involves the fuel used by cells under normal conditions and relies on an ongoing transfer of calcium between two cell components via an ion channel. Without this transfer, cells start consuming themselves as a way of to get enough energy.

28 Jul 2010